News: Insmed Incorporated (INSM.O)

INSM.O on Consolidated Issue listed on NASDAQ Capital Market

0.76USD
8 Dec 2009
Price Change (% chg)

$-0.05 (-6.17%)
Prev Close
$0.81
Open
$0.80
Day's High
$0.80
Day's Low
$0.76
Volume
469,672
Avg. Vol
370,125
52-wk High
$2.57
52-wk Low
$0.40

view news for:
Select another date:

Mon, Jul 27 2009

UPDATE 1-Insmed stops supplying Iplex to new patients

* Says has no longer the ability to manufacture the drug

Continue Reading

BEFORE THE BELL-Insmed shares down after Iplex move

NEW YORK, July 27 (Reuters) - Shares of Insmed Inc fell 9.3 percent to 97 cents in premarket trading on Monday, after the company said it would cease the supply of Iplex to any new patients.

HEADLINE STOCKS-Some U.S. stocks on the move on June 25

(Updates to after the open, adds Microsoft, Alcoa, SLM, Paychex, Kimberly-Clark, Boston Scientific and PetroQuest)

STOCKS NEWS US-SLM Corp rises after JPMorgan upgrade

For U.S. stock market report double-click [.N] 0910 ET 25June2009-SLM Corp rises after JPMorgan upgrade ------------------------------------------------------------------------------

UPDATE 1-Insmed drug fails in genetic disorder study, shrs tank

* Mid-stage genetic disorder study fails to show efficacy

HEADLINE STOCKS-Some U.S. stocks to watch on June 25

NEW YORK, June 25 (Reuters) - Some U.S. stocks to watch on Thursday:

STOCKS NEWS US-Dress Barn to buy Tween Brands in $157 mln deal

For U.S. stock market report double-click [.N] 0906 ET 25June2009-Dress Barn to buy Tween Brands in $157 mln deal ------------------------------------------------------------------------------

STOCKS NEWS US-Insmed plummets after Phase II trial data

For U.S. stock market report double-click [.N] 0858 ET 25June2009-Insmed plummets after Phase II trial data ------------------------------------------------------------------------------

BEFORE THE BELL-Insmed shares tank after trial results

NEW YORK, June 25 (Reuters) - Shares of Insmed Inc fell 50 percent to $1.17 in premarket trading on Thursday, after the company said a drug missed a majority of functional endpoints in a Phase II study.

U.S. allows Lou Gehrig's patients to try Insmed drug

WASHINGTON (Reuters) - U.S. regulators will allow experimental use of Insmed Inc's drug Iplex for some patients with Lou Gehrig's disease, the Food and Drug Administration said on Tuesday.

Select another date:

Market Views

» More INSM.O Market Views

Press Releases

view news for: